HOLDING STRONG!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is funny reading some of the posts regarding FDA letter regarding Adderall Shortage.
Some are not happy but it does not matter how they try to spin it, it is HUGE news for ELTP!!!
FDA letter regarding Adderall Shortage
August 1, 2023
Dear Americans,
As leaders of the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), we recognize the important role that prescription stimulants play in the treatment of conditions such as attention-deficit/hyperactivity disorder (ADHD), binge eating disorder, and uncontrollable episodes of deep sleep (narcolepsy). The lack of availability of certain medications in recent months has been understandably frustrating for patients and their families. Given the interest related to access to these medications, we want to provide an update on the ongoing actions being taken to resolve the shortages of prescription stimulant medications. In addition, we want to acknowledge important issues that will need to be addressed through longer-term coordination by a variety of entities involved in this effort. This is not a problem that the FDA and DEA can solve on our own. We are urging all stakeholders to work together to resolve these shortages as quickly as possible. The FDA and DEA do not manufacture drugs and cannot require a pharmaceutical company to make a drug, make more of a drug, or change the distribution of a drug. That said, we are working closely with numerous manufacturers, agencies, and others in the supply chain to understand, prevent, and reduce the impact of these shortages. The current shortage of stimulant medications is the result of many factors. It began last fall due to a manufacturing delay experienced by one drug maker. While this delay has since resolved, we are continuing to experience its effects in combination with record-high prescription rates of stimulant medications. Data show that, from 2012 to 2021, overall dispensing of stimulants (including amphetamine products and other stimulants) increased by 45.5 percent in the United States. According to a U.S. Centers for Disease Control and Prevention report, particularly during 2020-2021, when virtual prescribing was permitted on a widespread basis during the COVID-19 Public Health Emergency, the percentages in certain age groups grew by more than 10 percent. We are calling on key stakeholders, including manufacturers, distributors, pharmacies, and payors, to do all they can to ensure access for patients when a medication is appropriately prescribed. We want to make sure those who need stimulant medications have access. However, it is also an appropriate time to take a closer look at how we can best ensure these drugs are being prescribed thoughtfully and responsibly. Stimulants are controlled substances with a high potential for abuse, which can lead to addiction and overdose. Therefore, there are limits (also known as quotas) set by DEA for how much of these drugs can be produced. However, for amphetamine medications, in 2022, manufacturers did not produce the full amount that these limits permitted them to make. Based on DEA's internal analysis of inventory, manufacturing, and sales data submitted by manufacturers of amphetamine products, manufacturers only sold approximately 70 percent of their allotted quota U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov Page 2 for the year, and there were approximately 1 billion more doses that they could have produced but did not make or ship. Data for 2023 so far show a similar trend. We (DEA and the FDA) have called on manufacturers to confirm they are working to increase production to meet their allotted quota amount. If any individual manufacturer does not wish to increase production, we have asked that manufacturer to relinquish their remaining 2023 quota allotment. This would allow DEA to redistribute that allotment to manufacturers that will increase production. DEA is also committed to reviewing and improving our quota process. The FDA is asking professional groups and healthcare providers to accelerate efforts to support appropriate diagnosis and treatment of ADHD, such as further development of additional clinical guidelines for ADHD in adults. In recognition of this need, FDA awarded a grant to the National Academies of Sciences, Engineering, and Medicine (NASEM) to support a scientific meeting on ADHD in adults and considerations for diagnosis and treatment. FDA also recognizes that further research is needed into the diagnosis and treatment of ADHD and believes that research can help inform the development of alternative treatments and an understanding of the behavioral and societal issues leading to widespread misuse of these medications in certain groups. FDA has already taken steps to support the development of alternative treatment options. In 2020, for instance, FDA permitted marketing of a game-based digital therapeutic to improve attention function in children with ADHD. This device offers a non-drug option for improving symptoms associated with ADHD in children. There are also non-stimulant medications approved to treat ADHD, including one approved in 2021. Additionally, to address continuing concerns of misuse, addiction and overdose of prescription stimulants, the FDA recently issued a drug safety communication and required updates to the labeling to standardize prescribing information and clearly inform patients, caregivers and healthcare professionals of these risks. FDA and DEA will continue to do all we can to prevent stimulant drug shortages, limit their impact, and resolve them as quickly as possible. We will consider additional actions to prevent non-medical use and identify efforts to better understand and strengthen the supply chain. We also hope that we can all work together to assure that those who need stimulant medications can get them based on the best clinical knowledge about when they are effective, and avoid them when there is no indication for their use. We will continue to work together and with all of you to mitigate this drug shortage and provide up to date information.
Sincerely,
Robert M. Califf, M.D.
Commissioner of Food and Drugs
U.S. Food and Drug Administration
Anne M. Milgram
Administrator Drug Enforcement Administration
Bloomberg - Adderall Shortage Has US Agencies Urging Drugmakers to Boost Output
GOOD NEWS FOR ELTP!!!
Link to FDA letter - https://www.fda.gov/media/170736/download?attachment
Is ELTP positioning for a deal?
MAZARS - Maximizing the deal value by identifying opportunities, managing risks, and sustaining value through integration.
we help companies to:
Define and strengthen your business rationale and key value drivers
Conduct financial, tax, operational, IT, regulatory, cybersecurity, and human capital due diligence
Identify risks, opportunities, and costs while maximizing integration value
Manage and mitigate risk through assessments, internal audits, controls, and corrective actions, data quality assessments, and data analytics
Develop clear, comprehensive integration plans and playbooks to increase transparency into integration efforts across all functions and protect against value erosion
Ensure successful transition and integration for employees, focused around a vision everyone can understand and be willing to embrace
This is great news! Pharmacies know Elite's product that Lannett introduced to them so Elite has a predetermined list of customers and they will get all the profits. This just cut out the middle man!!!
Orange Book search by company - it is still there!
Product Details for ANDA 214961
VIGABATRIN (VIGABATRIN)
500MG/PACKET
Marketing Status: Prescription
Active Ingredient: VIGABATRIN
Proprietary Name: VIGABATRIN
Dosage Form; Route of Administration: FOR SOLUTION; ORAL
Strength: 500MG/PACKET
Reference Listed Drug: No
Reference Standard: No
TE Code: AA
Application Number: A214961
Product Number: 001
Approval Date: Jun 24, 2022
Applicant Holder Full Name: ELITE LABORATORIES INC
Marketing Status: Prescription
Patent and Exclusivity Information
Interesting - Dexcel Pharma has Vigabatrin in the orange book as well.
Wonder if they helped Elite with it?
The partnership with Dexcel could be very beneficial to Elite!!!
On December 6, 2021, Elite Pharmaceuticals Inc. (“Elite”) signed a License and Distribution Agreement with Dexcel Ltd. (Or Akiva, Israel) to be the exclusive distributor of Elite’s generic version of Adderall® for Israel. Elite’s generic version of Adderall® is an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate). Adderall ® is a central nervous system (CNS) stimulant, indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. Dexcel will market the 10 mg, 20 mg, and 30 mg tablets. Elite will manufacture and package the generic product under Dexel’s label. Dexcel will provide sales, marketing, and distribution, at its own expense. Dexel will pay an agreed upon transfer price for the product and will share any profits when the net selling price exceeds a floor price.
Someone bought millions? Looking at the chart you see that millions were bought up to $.048..... little red lines show some very small sales to pull ELTP price back down. What is up??? Someone positioning??? Using rough numbers of 3mil shares with just a 5 cent pop - that is a $150,000 profit.
Elite’s discussion on financials-
So let's start with the P&L, where we reported another double digit growth in revenues that makes seven quarters in a row now, where we have achieved double or triple digit revenue growth on a year-on-year basis. Revenues for the quarter ended December 2020 were $6.05 million as compared to $5.05 million with the December 2019 quarter, so that’s $1 million increase or 20% as compared to the same quarter last year. The increase was driven by revenues from generic extended release Adderall, which was launched on March 30th of this year. We also saw strong growth as compared to last year for generic immediate release Adderall and generic Dantrolene capsules.
Our other products Isradipine, Phentermine, Phendimetrazine and Naltrexone also continued their consistent performance, with continuing solid contributions to revenues. While Phentermine, Naltrexone and Phendimetrazine do provide a stable revenue as they've done for many years now. It's the generic Adderall, and Isradipine products that continue to stand out as the growth driver, both retrospectively as evidenced by revenues reported and prospectively, with certain factors seeming to indicate additional future upside for these products.
Remember, our generic Adderall products are still relatively new in the market. We launched the immediate release product just a little over a year ago. And we launched the extended release product less than a year ago, only nine months or so. And our alliance partner with these products Lannett, they continue to do an excellent job penetrating the market, and they should continue expanding market share.
Elite’s discussion on debt-
Elite on the other hand, we've been developing products, we've been commercializing products, but without incurring anywhere near the level of debt incurred by so many others in the industry. Our growth has been financed at first, through equity financing, and for most of this fiscal year from internal cash flows alone, no debt. I repeat that. No debt.
So when we talk about fundamentals being in place, there is three debt-related ratios that I focus on. And all three demonstrate just how relatively debt free we are in comparison to some of our peers in the generic market.
First is the ratio of long-term debt to current market cap. Now Elite’s long-term debt is less than 5% of our market cap. That compares to Teva, which is 190%, Amneal 340%, and Endo, which is 400%. So these companies, they each have loans that are two, three and four times their market caps and Elite is just the opposite. It's our market cap that's larger, and it's more than 20 times that of our long-term loans.
Second ratio, our focus on a lot is the ratio between long-term debt and equity. So Elite’s long-term debt is approximately 21% of its equity. And that compares with Teva, which is 202%, Amneal 973% and Endo, which has negative equity and more than $8 billion in long-term debt. So Elite’s debt is a fraction of its equity, while others have debts that are multiples of their equity.
The third ratio that really sticks out is the times interest earned ratio and that measures EBIT -- Earnings Before Interest and Taxes in relation to interest expense. So this is a ratio where the higher number indicates stronger financials due to revenues being greater than underlying debt and interest expense. So Elite’s times interest ratio is 18 that’s compared to three for Teva and one for Amneal, and one for Endo.
So this means that thanks to our low level of debt, we have a much greater percentage of earnings available for product development as compared to other companies, which have debt and interest expense that consume large portions of their earnings, leaving less available for product development. So one of the reasons why we're able this year to fund product development internally – from internal cash flows.
So if you ask me about the status of an uplisting, I would say that everything we need to do and need to see from a financial standpoint is coming together. The fundamentals on the P&L statement, the cash flow statement and the balance sheet they've improved substantially, and are actually in some cases among the strongest in our sector. This is on the critical path to achieving the uplisting and we're doing well in meeting this.
So to sum things up from a finance perspective, our financials continue to strengthen, revenues are up, cash flow is positive, debt is low -- very low, and the ratios and fundamentals are coming together on target. You know, things don't always go as planned, but this is going as planned and it's nice to see so much being on track.
Elite (ELTP) facts below -
This OTC stock is actually generating revenues and making a profit!
Elite Pharmaceutical (ELTP)!!! Should be trading at least in the 40 cent range or higher, IMO!
Reporting quarterly results in the next week.
ELTP - generic Adderall IR IQVIA $400 million market - LAUNCHED and generating REVENUE!
revenue
ELTP - generic Adderall IR IQVIA $1.5 Billion market - LAUNCHED and generating REVENUE!
The competitive generic Adderall market (IR & XR) is almost $2 billion, with a CAGR of between 6% and 8.5%.
Using a conservative mid-point for the CAGR and a prorated market share suggests Elite could reach $225,000,000 scaling up to peak revenues (3-5 years) with just with Adderall revenues.
Then you can also add in ELTP's other approved products (Isradipine, Loxapine, Phentermine, generic Revia, generic Bontril, generic Surmontil, generic Dantrium).
AND, there will be other sources of revenue generated by their R&D efforts.
Working on a new product-
Quote from CEO Nasrat - “This is an outstanding product for us once we get an approval because we will be the fifth in this arena, and even if there were more people than that and we've got just 10% of that market, that's $160 million, a $160 million in revenues will do wonders to Elite stock.
Profit Last Quarter $2.5 Million and continues to grow quarter after quarter!
CASH FLOW POSITIVE!
Reoccurring Profits
61% YOY gains.
CASH FLOW POSITIVE 2 quarters in a row.
Forward PE 5.6??? That is way too low!
6 straight quarters of double and triple digit gains YOY.
Elite doing All R&D in-house currently.
Elite has competitive advantage on high entry barrier ER formulas.
Elite streamlining using SAP technology.
Debt to market cap : 7%
“Elite is attractive for Merger or BuyOut”.
New Equipment for production line - NEW 30 cubic foot V-blender. NEW higher speed tablet press. Facility upgrades. One shift can do 300 million capsules a month.
Upgraded the Packaging Line - capacity increased by 25%.
ELITE's partners Lannett, Glenmark, and Tagi continue to penetrate the markets.
Walgreens - Largest Customer - 15% of market
$75 million tax credit, no taxes on first $75 million profit.
49% profitability.
Partnerships, contract development, licensing opportunities, contract manufacturing, new ANDAs, potential for merger, potential for buy out, etc!!!
All of this has been posted here before. As always, do your own due dilegence and invest wisely!
No Je, that is not Nasrat's job! Nasrat's job is exactly what he has been doing - Leading Elite. He has faced challenges but he recovered and has brought revenues to ELTP which have been increasing!
IT IS OUR JOB to get the word out about Elite's success!
In all stocks the Company does the work but it is the discussion and talk by investors about a company's successes that move the PPS!
So get out there and TALK about ELITE!!!
Start spreading the news!
I'm leaving (OTC) today
I (ELTP) want to be a part of it
New York, New York (NYSE)
LOL, lets have some fun! GET THE ELTP WORD OUT!!!
LOL, it is fun to see ELTP with a little jump with early high volume causing some to get all flustered!!!
Prospect of continued increasing record revenue to be reported next week!
Elite has been quite and not putting out fluff news so we don't know what great things we may hear!
Fear of squeeze with a major rise in PPS is a valid CONCERN for those not in the right position!
SPREAD THE WORD!!! GET THE ELTP MESSAGE OUT THERE!!!
ALL DEDICATED ELTP INVESTORS MUST TALK ABOUT ELITE PHARMACEUTICALS EVERYWHERE THEY CAN!!!
GIVE THE FACTS - INCREASING REVENUE QUARTER AFTER QUARTER, CASH FLOW POSITIVE, GROWING THEIR MARKET BASE, ETC!!!
NO ONE IS DOING IT FOR US SO - GET THE WORD OUT!!!
Just saw a post regarding ELITE on reddit. We need more communications out there letting people know about ELTP and how undervalued/oversold Elite is.
We have to get the word out and generate INTEREST!
I have an account now but it will be 30 days before I can share anything.
Everyone that actually wants Elite to be known then we have to get the word out on the right message platforms that are hot and trending.
Get the word out and send them here to IHUB!!!
ELITE's revenues have been going up! ELITE's profits have been going up!
ELITE's stock price has been pushed down! ELITE's stock is way oversold!
ELITE should be trading at least in the 40 cent range!
If we say something on WSB and other retail investors decide to take a position in ELITE based on their own due diligence then I say spread the word!!!
ELITE could have a headline like this very soon!
"OMG “Tiny oil driller with 5 employees” becomes $128m company in three hours due to mention on WSB"and in the article "soaring nearly 1,000%".
Just a mention on wallstreetbets and a stock that has been abused for so long can be sky rocketing.
We need an ELITE army posting on reddit WSB!!!
ELITE in not overvalued, is increasing revenues and growing, and for longer than the the past year of trading has shown us how oversold ELITE is!
Read - "GameStop: History Points To A Share Price In The Thousands"
Yes, I am going back to the current situation with GameStop!
There are a lot of similarities with ELITE's situation.
Pay attention to the story and realize the power of this statement -
"That all changed when a mob of savvy retail investors realized that it wouldn't take much to ignite........"
That is exactly what ELITE needs to right the injustice that has plagued our stock for too long now!!!!!!!!
That is what ELITE needs a gamestop story!
Institutional big boys jump in to drive a stock down and then a huge group of retail investors connect on social media platforms to fight back.
Maybe ELTP is getting a following on WallStreetBets forum???
Maybe we will see ELITE's stock price run up like GameStop!!!
N2K, in support of controlling cost - "increase in gross margin is due to increased manufacturing efficiencies"
As stated in Elite's current report -
"Our gross profit margin was 49% during the three months ended September 30, 2020 as compared to 29% during the three months ended September 30, 2019. The increase in gross margin is due to increased manufacturing efficiencies of scale being achieved in relation to increased manufacturing volumes resulting in decreased unit overhead absorption rates, as compared to the comparable period of the prior year, combined with timing of in market sales by our marketing partner of the Amphetamine IR and Dantrolene products resulting in a higher level of related licensing fees during the three months ended September 30, 2020, as compared to the comparable period of the prior fiscal year."
So is Elite's amphetamine salts what is mentioned in Lannett Inc (LCI) Q4 2020 Earnings Call Transcript? CNS is up!!!
*******************************************
Scott Henry -- Roth Capital Partners -- Analyst
Okay. Final question. The CNS category was strong in 2020 fiscal year, but it tends to be a little more volatile, a lot more levers. How should we think about CNS for fiscal year 2021?
John Kozlowski -- Vice President of Finance and Chief Financial Officer
Well, if you see it in Q4, CNS is up and that's due to -- specifically due to one of our more recent launches, the amphetamine salts. And so as we look in 2021, we are expecting that category to grow starting in Q1 where we're getting a full quarter.
*******************************************
So, Lannett is expecting CNS amphetamine salts to GROW in their Q1 (July through September) which means MORE FOR ELTP!!!
JEEZZZ! Elite could buy with shares but SUNGEN wanted all CASH for their part of the adderall generics!
Carter was right - Elite's cash is needed for operations and R&D therefore they did not have the cash available!
It was smart to keep the focus on Elite's cash needs and not try to raise cash by dumping shares through Lincoln Park Capital. SUNGEN may not have waited for Elite to sell shares and may have already had a unknown bidder ready to offer cash so time was of concern.
Key is we do not know all the details and we never will as WE DO NOT HAVE THE LEGAL RIGHT to know it ALL!!! Get over it already! Things are still good for ELITE!!!
It is great that Nasrat bought SUNGEN's interest in the adderall generics as we know that he is committed to ELITE's success and will look out for ELITE's best interest as that is in his best interest. What if a SUNGEN sold their interest to someone that created problems for ELITE??
Elite still gets their share of the adderall generics!
Elite's revenue will continue to increase from the adderall generics!
Elite will have no problems with adderall generics as Nasrat is the new partner and not some unknown trouble maker!
Elite can focus their cash where they need it the most (i.e., getting the next 1.5 billion generic developed, approved, launched)!
ELTP recent time & sales
Date/Time Price Shares Buy/Sale
07/01/2020 13:18:10 EDT 0.0743 20000
07/01/2020 13:18:10 EDT 0.0743 700
07/01/2020 13:16:47 EDT 0.0743 800
07/01/2020 13:16:47 EDT 0.0743 3000 S
07/01/2020 13:16:45 EDT 0.075 10000
07/01/2020 13:16:43 EDT 0.075 20000 S
07/01/2020 13:16:42 EDT 0.08 33
07/01/2020 13:16:33 EDT 0.08 154100
07/01/2020 13:16:33 EDT 0.08 1750 S
07/01/2020 13:16:21 EDT 0.0801 10000 S
07/01/2020 13:05:39 EDT 0.0808 400 B
07/01/2020 13:04:28 EDT 0.08055 250 S
07/01/2020 13:03:39 EDT 0.0808 10000 S
07/01/2020 12:56:34 EDT 0.0815 48750
07/01/2020 12:45:27 EDT 0.0815 12812
07/01/2020 12:45:26 EDT 0.0815 47188
07/01/2020 12:41:54 EDT 0.0815 1000 B
07/01/2020 12:41:00 EDT 0.0808 89 S
07/01/2020 12:38:12 EDT 0.0815 10000 B
07/01/2020 12:38:12 EDT 0.0814 10000 S
07/01/2020 12:37:47 EDT 0.0815 460 S
07/01/2020 12:35:29 EDT 0.082 540 S
07/01/2020 12:28:22 EDT 0.0833 600 B
07/01/2020 11:57:04 EDT 0.08122 2180 S
07/01/2020 11:35:50 EDT 0.082 9000 B
07/01/2020 11:32:26 EDT 0.08077 5400 B
07/01/2020 11:24:28 EDT 0.0801 15000 S
07/01/2020 11:24:28 EDT 0.08077 5000 S
07/01/2020 11:18:56 EDT 0.0812 20000 S
07/01/2020 11:18:46 EDT 0.0815 2000
From Elite's conf call - some key exerts IMO!
**What I know and that is the quarter ending today (June 30, 2020 which will be reported around August 14, 2020) we will hit the $7 million in revenues and that quarter would not have any profit splits from the ER
**The growing concern -- there is no going concern opinion that's been removed and I mean the business and the financials demonstrate just why that was the case. We don't have that issue and on the internal controls, there were material weaknesses in internal controls in the 2019 10-K, all of which have been remediated.
*Revenues 137% % increase as compared to the last year. So clearly without a doubt these are our highest revenues, as well as the largest dollar increase in our revenues in Elite's history.
*Manufacturing revenues, those are earned when we make and we ship the product. So those increased from $5.4 million in 2019 to $14.5 million in 2020. It's a $9.1 million increase or a 166%.
*We do expect additional contribution from the extended release Adderall as those profit splits start to come online over the next few quarters. So you put the increases in both manufacturing revenues and profits put together, you get total revenues going up from $7.6 million to $18 million in a single year.
*Our marketing partner has done a great job with all of these products, but there's still room for growth in the future.
*We secured enough API quota from the DEA to support Lannett's sales projections through the end of this year. That is fantastic news. We struggled with that in the first quarter and a little bit in the second and finally the DEA came around and gave us enough quota to support the sales and marketing projections through the end of the year.
*Our sales and marketing partners Glenmark, TAGI and Lannett are all performing well.
*CNS, ANDA, what is the status of SunGen partnership CNS, ANDA with the potential of $1.5 billion market? As it would require a bio equivalency trial before submitting and we were led to believe this effort was on the front burner. Why the delay? Well, the delay is because SunGen is not putting in any money. So I reached an agreement with SunGen that we will take over this product. We have no further obligation to them. We are going to develop it to a point where we can run a clinical trial. And it will be 100% Elite's product.
*Yes. I think August 14th is the next filing date.
Gap just filled.... T&S below
Date/Time Price Shares Buy/Sale
06/30/2020 10:44:29 EDT 0.08975 100 S
Elite T&S updated with B-buy and S-sale
Date/Time Price Shares Buy/Sale
06/30/2020 10:34:26 EDT 0.09 1218
06/30/2020 10:33:43 EDT 0.09 1000
06/30/2020 10:25:54 EDT 0.09 400
06/30/2020 10:22:23 EDT 0.09 1420
06/30/2020 10:22:20 EDT 0.09 5000
06/30/2020 10:22:14 EDT 0.09 2500
06/30/2020 10:22:11 EDT 0.09 10000 S
06/30/2020 10:22:02 EDT 0.091 30000 B
06/30/2020 10:20:57 EDT 0.09 14000
06/30/2020 10:20:57 EDT 0.09 1000
06/30/2020 10:20:57 EDT 0.09 30000
06/30/2020 10:20:57 EDT 0.09 5000 S
06/30/2020 10:20:35 EDT 0.0907 10000 S
06/30/2020 10:20:16 EDT 0.091 10000 S
06/30/2020 10:19:55 EDT 0.092 2500 S
06/30/2020 10:18:50 EDT 0.0923 11322 B
06/30/2020 10:16:58 EDT 0.091 9500
06/30/2020 10:16:55 EDT 0.091 10000
06/30/2020 10:16:51 EDT 0.091 30500 S
06/30/2020 10:14:46 EDT 0.095 1000 B
06/30/2020 10:14:23 EDT 0.0937 1000 B
06/30/2020 10:14:07 EDT 0.0936 591 B
06/30/2020 10:12:53 EDT 0.093 100 S
06/30/2020 10:10:22 EDT 0.0935 500 B
06/30/2020 10:09:27 EDT 0.091 19550 S
06/30/2020 10:09:09 EDT 0.095 73 B
06/30/2020 10:07:08 EDT 0.0935 485 S
06/30/2020 10:06:32 EDT 0.0959 250 B
06/30/2020 10:01:41 EDT 0.0935 1000 S
06/30/2020 10:01:08 EDT 0.0959 125 B
06/30/2020 9:58:21 EDT 0.0935 1000 S
06/30/2020 9:55:57 EDT 0.096 200
06/30/2020 9:55:49 EDT 0.096 10000 S
06/30/2020 9:55:38 EDT 0.097 20000 B
06/30/2020 9:55:38 EDT 0.0965 20000 S
06/30/2020 9:54:33 EDT 0.097 830 B
06/30/2020 9:54:13 EDT 0.0965 2500 S
06/30/2020 9:54:02 EDT 0.097 9180 B
06/30/2020 9:52:54 EDT 0.0969 10000 S
06/30/2020 9:51:14 EDT 0.0978 4396 B
06/30/2020 9:50:55 EDT 0.0969 1000
06/30/2020 9:50:25 EDT 0.0969 563 S
06/30/2020 9:49:34 EDT 0.0978 400 B
06/30/2020 9:49:25 EDT 0.0969 1999 S
06/30/2020 9:48:48 EDT 0.0972 10000 S
06/30/2020 9:48:27 EDT 0.0978 10000
06/30/2020 9:48:27 EDT 0.0978 7000
06/30/2020 9:47:31 EDT 0.0978 3900 S
06/30/2020 9:46:45 EDT 0.0995 3800 B
06/30/2020 9:46:43 EDT 0.099 4997 B
06/30/2020 9:46:43 EDT 0.0989 2502
06/30/2020 9:46:42 EDT 0.0989 2500 B
06/30/2020 9:46:42 EDT 0.0975 2500 S
06/30/2020 9:45:17 EDT 0.0989 7499 B
06/30/2020 9:45:16 EDT 0.0975 2500 S
06/30/2020 9:44:44 EDT 0.0989 25000
06/30/2020 9:44:43 EDT 0.0989 7499 B
06/30/2020 9:44:43 EDT 0.0975 2500 S
06/30/2020 9:36:30 EDT 0.0976 2700 B
06/30/2020 9:35:29 EDT 0.097 2000 B
06/30/2020 9:34:44 EDT 0.095 215
06/30/2020 9:34:06 EDT 0.095 5900 S
06/30/2020 9:33:59 EDT 0.099 4100 S
06/30/2020 9:32:55 EDT 0.0993 1000 B
06/30/2020 9:32:26 EDT 0.095 40000 S
06/30/2020 9:32:06 EDT 0.099 141000 S
06/30/2020 9:32:01 EDT 0.0995 1 B
06/30/2020 9:31:56 EDT 0.099 10000
06/30/2020 9:31:40 EDT 0.099 85000
06/30/2020 9:31:38 EDT 0.099 100000
06/30/2020 9:30:53 EDT 0.099 20000
06/30/2020 9:30:50 EDT 0.099 40000
06/30/2020 9:30:27 EDT 0.099 10600 B
06/30/2020 9:30:27 EDT 0.098 30000 B
06/30/2020 9:30:08 EDT 0.097 20000 S
06/30/2020 9:30:07 EDT 0.0972 1000
06/30/2020 9:30:07 EDT 0.0972 12000
06/30/2020 9:30:07 EDT 0.0972 20000
06/30/2020 9:30:07 EDT 0.0972 29915 B
06/30/2020 9:30:02 EDT 0.09 5000 S
06/30/2020 9:30:00 EDT 0.098 30000
Elite time and sales below
Date/Time Price Shares
06/30/2020 10:34:26 EDT 0.09 1218
06/30/2020 10:33:43 EDT 0.09 1000
06/30/2020 10:25:54 EDT 0.09 400
06/30/2020 10:22:23 EDT 0.09 1420
06/30/2020 10:22:20 EDT 0.09 5000
06/30/2020 10:22:14 EDT 0.09 2500
06/30/2020 10:22:11 EDT 0.09 10000
06/30/2020 10:22:02 EDT 0.091 30000
06/30/2020 10:20:57 EDT 0.09 14000
06/30/2020 10:20:57 EDT 0.09 1000
06/30/2020 10:20:57 EDT 0.09 30000
06/30/2020 10:20:57 EDT 0.09 5000
06/30/2020 10:20:35 EDT 0.0907 10000
06/30/2020 10:20:16 EDT 0.091 10000
06/30/2020 10:19:55 EDT 0.092 2500
06/30/2020 10:18:50 EDT 0.0923 11322
06/30/2020 10:16:58 EDT 0.091 9500
06/30/2020 10:16:55 EDT 0.091 10000
06/30/2020 10:16:51 EDT 0.091 30500
06/30/2020 10:14:46 EDT 0.095 1000
06/30/2020 10:14:23 EDT 0.0937 1000
06/30/2020 10:14:07 EDT 0.0936 591
06/30/2020 10:12:53 EDT 0.093 100
06/30/2020 10:10:22 EDT 0.0935 500
06/30/2020 10:09:27 EDT 0.091 19550
06/30/2020 10:09:09 EDT 0.095 73
06/30/2020 10:07:08 EDT 0.0935 485
06/30/2020 10:06:32 EDT 0.0959 250
06/30/2020 10:01:41 EDT 0.0935 1000
06/30/2020 10:01:08 EDT 0.0959 125
06/30/2020 9:58:21 EDT 0.0935 1000
06/30/2020 9:55:57 EDT 0.096 200
06/30/2020 9:55:49 EDT 0.096 10000
06/30/2020 9:55:38 EDT 0.097 20000
06/30/2020 9:55:38 EDT 0.0965 20000
06/30/2020 9:54:33 EDT 0.097 830
06/30/2020 9:54:13 EDT 0.0965 2500
06/30/2020 9:54:02 EDT 0.097 9180
06/30/2020 9:52:54 EDT 0.0969 10000
06/30/2020 9:51:14 EDT 0.0978 4396
06/30/2020 9:50:55 EDT 0.0969 1000
06/30/2020 9:50:25 EDT 0.0969 563
06/30/2020 9:49:34 EDT 0.0978 400
06/30/2020 9:49:25 EDT 0.0969 1999
06/30/2020 9:48:48 EDT 0.0972 10000
06/30/2020 9:48:27 EDT 0.0978 10000
06/30/2020 9:48:27 EDT 0.0978 7000
06/30/2020 9:47:31 EDT 0.0978 3900
06/30/2020 9:46:45 EDT 0.0995 3800
06/30/2020 9:46:43 EDT 0.099 4997
06/30/2020 9:46:43 EDT 0.0989 2502
06/30/2020 9:46:42 EDT 0.0989 2500
06/30/2020 9:46:42 EDT 0.0975 2500
06/30/2020 9:45:17 EDT 0.0989 7499
06/30/2020 9:45:16 EDT 0.0975 2500
06/30/2020 9:44:44 EDT 0.0989 25000
06/30/2020 9:44:43 EDT 0.0989 7499
06/30/2020 9:44:43 EDT 0.0975 2500
06/30/2020 9:36:30 EDT 0.0976 2700
06/30/2020 9:35:29 EDT 0.097 2000
06/30/2020 9:34:44 EDT 0.095 215
06/30/2020 9:34:06 EDT 0.095 5900
06/30/2020 9:33:59 EDT 0.099 4100
06/30/2020 9:32:55 EDT 0.0993 1000
06/30/2020 9:32:26 EDT 0.095 40000
06/30/2020 9:32:06 EDT 0.099 141000
06/30/2020 9:32:01 EDT 0.0995 1
06/30/2020 9:31:56 EDT 0.099 10000
06/30/2020 9:31:40 EDT 0.099 85000
06/30/2020 9:31:38 EDT 0.099 100000
06/30/2020 9:30:53 EDT 0.099 20000
06/30/2020 9:30:50 EDT 0.099 40000
06/30/2020 9:30:27 EDT 0.099 10600
06/30/2020 9:30:27 EDT 0.098 30000
06/30/2020 9:30:08 EDT 0.097 20000
06/30/2020 9:30:07 EDT 0.0972 1000
06/30/2020 9:30:07 EDT 0.0972 12000
06/30/2020 9:30:07 EDT 0.0972 20000
06/30/2020 9:30:07 EDT 0.0972 29915
06/30/2020 9:30:02 EDT 0.09 5000
06/30/2020 9:30:00 EDT 0.098 30000
n2k, I am with you on that. Was expecting more! Was it COVID on ? Was it COVID related impacts to the distribution network and our partners' difficulties? Was it DEA quota to ELITE? Was it difficulty in getting active pharmaceutical ingredients to manufacture ELITE's products? Was it needing additional shifts to manufacture more products?
Got to admit that staying flat in January to March 2020 is still good considering how CRAZY the whole world is right now!
Not worried as ELITE is in business and working and GROWING!!!
Just imagine what they can do if we get back to some kind of normal.
ELITE got a 137% YOY increase with little ole Adderall ER and a $400M market.
Adderall XR will give an ADDITIONAL 445% increase to ELITE with a $1.3 BILLION market!
August 2020 10Q quarterly report is just 6 weeks away or approximately reporting on August 11th (best guess)!!!
We did see some bigger spreads in ELTP trading. 0.07 to 0.08 vs 0.0XXXXX, one penny spread vs sub-sub-sub penny spreads.
Was that GTS???
If GTS sticks around and we have a good 10-K and expecting a great August 10-Q, there could be huge run up coming!
Could GTS be joining in because they see a HUGE jump in ELTP's share price coming???
The MM that showed up on ELITES trades GTSM is GTS. GTS is a leading global electronic market maker, powered by combining market expertise with innovative, proprietary technology.
GTS is one of the top MMs on NYSE so why is this BIG player working their high speed trading on ELTP???
Cut from something I found for GTS and OTC trading.....
That's starting to change thanks to efforts by some of Wall Streets most sophisticated players applying technology to the outdated market. Citadel Securities, Virtu Financial, Jane Street, and GTS ranked in the top five in ADR trading for notional amount and number of trades in July on OTC Markets' alternative trading system. G1 Execution Services, a subsidiary of Susquehanna, fell just outside the top five for both categories.
There is no doubt about the opportunity in the market. ADRs pricing spreads can often be much wider than listed stocks as brokers account for the risk that comes with conducting the labor-intensive trades. As a result, some investors choose to steer clear of ADRs entirely, or trade sparingly, despite interest in the companies.
GTS is one of the more recent entrants into the space, following its acquisition of Cantor Fitzgerald's wholesale market-making business in November 2018. Joe Pleffner, a principal in GTS' wholesale market-making business who came over as part of the Cantor deal, stressed that while trading ADRs has greatly evolved over the years, it's still not a pure speed game, as is commonly the case for listed equities.
Technology and humans are equally important to GTS' growth in the space, he added.
"Just because I am really fast in OTC markets doesn't mean I am really efficient in giving my customers the best price," Pleffner told Business Insider. "In some instances, especially OTC securities and even small caps, speed is not really beneficial to the investor. It is really where can I add more liquidity. Where can I give the best price to my clients. A lot of times the lack of speed kind of helps."
freerealtime has time&sales for ELTP.
It is really interesting to look at the sales and buys.
Someone buys at 0.08 and it is followed by a dump at 0.07
WOW, look at the ELTP games on level 2 buys/sells!
This IS a coordinated hit to steal shares!!!
Will be interesting to see the % shorted for today.
10K release Friday June 26 after market close with CC on Monday.
Just my guess!
Sharkey1 - Control number! Use the control number (16 digits) as the CUSIP (9 digits) probably will not get you in to Elite's meeting.
In the email I received from TDAmeritrade it shows-
ELITE PHARMACEUTICALS, INC. has issued proxy materials for its 2020 Special Meeting of shareholders.
Meeting Date: June 23, 2020
Record Date: April 27, 2020
CUSIP Number: XXXXXXXXX
Control Number: XXXXXXXXXXXXXXXX
The CONTROL NUMBER for the ELTP shareholder meeting is on the email you received for the proxy vote!
To attend the meeting, go to https://web.lumiagm.com/289761342, click on “I have a login,” enter the CONTROL NUMBER found on your proxy card you previously received, and enter the password “elite2020”
ELTP SEC Annual Report 10-Q previous dates
2019-06-21
2018-06-14
2017-06-14
2016-06-15
2015-06-15
2014-06-30
2013-06-21
2012-06-29
2011-06-29
Elite is not late! Could be tomorrow, could in two weeks from tomorrow.
ELITE's volume of shares
shorted on the below days is crazy!
May 29th Short-462,356 - 45% of total Vol Shorted
May 26th Short-832,408 - 87% of total Vol Shorted
May 22nd Short-227,101 - 88% of total Vol Shorted
May 21st Short-175,222 - 51% of total Vol Shorted
May 18th Short-465,898 - 68% of total Vol Shorted
May 15th Short-352,900 - 74% of total Vol Shorted
May 14th Short-201,588 - 57% of total Vol Shorted
May 13th Short-313,654 - 55% of total Vol Shorted
May 12th Short-418,014 - 66% of total Vol Shorted
May 05th Short-650,501 - 66% of total Vol Shorted
Thanks JB